Western blot analysis was performed using nuclear enriched extracts (30 µg lysate) of MDA-MB-231 (Lane 1) and T-47D (Lane 2). The blots were probed with Anti-p53 Mouse Monoclonal Antibody (Product # MA5-11296, 0.5-2 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 µg/mL, 1:2500 dilution). A 53 kDa band corresponding to p53 was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody using iBind™ Flex Western Starter Kit (Product # SLF2000S). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant Human p53 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|ChIP assay (ChIP)||5 µg|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||0.5-2 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 12 publications below|
|Miscellaneous PubMed (MISC)||See 2 publications below|
|Immunohistochemistry (IHC)||See 5 publications below|
|ChIP assay (ChIP)||See 1 publications below|
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
|Immunocytochemistry (ICC)||See 2 publications below|
MA5-11296 targets p53 in FACS, IP, and WB applications and shows reactivity with Human samples.
The MA5-11296 immunogen is recombinant Human p53 protein.
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons
IP-MS enrichment of TP53 (LFQ intensity): TP53 was enriched 2151-fold from BT549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and TP53 antibody (Part No. MA5-11296). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell proliferation.
MA5-11296 was used in western blot to characterize inhibition of neuronal tumor cell proliferation by mitochondrial ferritin
|Shi ZH,Shi FF,Wang YQ,Sheftel AD,Nie G,Zhao YS,You LH,Gou YJ,Duan XL,Zhao BL,Xu HM,Li CY,Chang YZ||Cellular and molecular life sciences : CMLS (72:983)||2015|
Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
MA5-11296 was used in western blot to characterize a melanoma cell line with a novel deletion/substitution from CC to T in the shared exon 2 of p14ARF/p16
|Williams RT,Barnhill LM,Kuo HH,Lin WD,Batova A,Yu AL,Diccianni MB||PloS one (9:null)||2014|
Increase in clusterin forms part of the stress response in Hodgkin's lymphoma.
MA5-11296 was used in western blot to study clusterin in Hodgkin's lymphoma-derived cell lines.
|Frazzi R,Casali B,Iori M,Nicoli D,Mammi C,Merli F||International journal of oncology (38:677)||2011|
Functional four-base A/T gap core sequence CATTAG of P53 response elements specifically bound tetrameric P53 differently than two-base A/T gap core sequence CATG bound both dimeric and tetrameric P53.
MA5-11296 was used in western blot to study the binding of tetrameric and dimeric p53 to two-base or four-base A/T gap core sequences
|Cai BH,Chen JY,Lu MH,Chang LT,Lin HC,Chang YM,Chao CF||Nucleic acids research (37:1984)||2009|
Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: implications for radio sensitization.
MA5-11296 was used in western blot to study the effects of ionizing radiation and 2-deoxyglucose on the transcriptome of a malignant glioma cell line and the significance for 2-deoxyglucose-induced radiosensitization
|Heminger K,Jain V,Kadakia M,Dwarakanath B,Berberich SJ||Cancer biology and therapy (5:815)||2006|
Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2.
MA5-11296 was used in western blot to study the therapeutic potential of adenovirus encoding degradation-resistant p53 variants for enhanced oncolysis of cancer cells
|van Beusechem VW,van den Doel PB,Gerritsen WR||Molecular cancer therapeutics (4:1013)||2005|
MdmX represses E2F1 transactivation.
MA5-11296 was used in western blot to study the p53- and Mdm2-independent inhibition of E2F1 transactivation by MdmX
|Wunderlich M,Ghosh M,Weghorst K,Berberich SJ||Cell cycle (Georgetown, Tex.) (3:472)||2004|
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
MA5-11296 was used in western blot to study the role of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
|Chandra J,Hackbarth J,Le S,Loegering D,Bone N,Bruzek LM,Narayanan VL,Adjei AA,Kay NE,Tefferi A,Karp JE,Sausville EA,Kaufmann SH||Blood (102:4512)||2003|
G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells.
MA5-11296 was used in western blot to study the effect of microtubule-destabilizing agents on cell-cycle arrest in human breast cancer cells
|Blajeski AL,Phan VA,Kottke TJ,Kaufmann SH||The Journal of clinical investigation (110:91)||2002|
|Not Applicable||Not Cited||
Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone.
MA5-11296 was used in western blot to study the expression of MDM2 by the stromal and giant cells present in giant cell tumors of bone
|Evdokiou A,Atkins GJ,Bouralexis S,Hay S,Raggatt LJ,Cowled PA,Graves SE,Clayer M,Findlay DM||International journal of oncology (19:625)||2001|
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
MA5-11296 was used in western blot to generate and characterize a mouse mammary tumor cell line with polyomavirus middle T antigen
|Nielsen LL,Gurnani M,Shi B,Terracina G,Johnson RC,Carroll J,Mathis JM,Hajian G||Cancer research (60:7066)||2000|
E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.
MA5-11296 was used in western blot to study the role of the ubiquitin-proteasome pathway in the mechanism by which the HPV-16 E7 protein induces retinoblastoma protein degradation
|Boyer SN,Wazer DE,Band V||Cancer research (56:4620)||1996|
Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation.
MA5-11296 was used in western blot to study the cellular changes induced by resveratrol using Hodgkin lymphoma-derived L-428 cells.
|Frazzi R,Valli R,Tamagnini I,Casali B,Latruffe N,Merli F||International journal of cancer (132:1013)||2013|
Immunohistochemical analysis of candidate gene product expression in the duodenal epithelium of children with coeliac sprue.
MA5-11296 was used in immunohistochemistry (paraffin) to determine the immunoexpression of deleted in colon cancer, p53, E-cadherin, and beta-catenin in the duodenal mucosa of children with coeliac disease.
|Barshack I,Goldberg I,Chowers Y,Weiss B,Horowitz A,Kopolovic J||Journal of clinical pathology (54:684)||2001|
Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study.
MA5-11296 was used in immunohistochemistry to study the influence of the phenotype of apoptosis-associated proteins on the clinical significance of cathepsin D expression in non-small cell lung cancer
|Fan C,Lin X,Wang E||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (33:1045)||2012|
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
MA5-11296 was used in immunohistochemistry to evaluate mucin and p53 expression as prognostic markers for stage IB non-small cell lung cancer
|Graziano SL,Gu L,Wang X,Tatum AH,Vollmer RT,Strauss GM,Kratzke R,Dudek AZ,Vokes EE,Green MR||Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (5:810)||2010|
Diagnosing xeroderma pigmentosum group C by immunohistochemistry.
MA5-11296 was used in immunohistochemistry to develop an immunohistochemical method for the diagnosis of xeroderma pigmentosum group C
|de Feraudy S,Boubakour-Azzouz I,Fraitag S,Berneburg M,Chan L,Chew K,Clericuzio CL,Cunningham B,Tope WD,Cleaver JE||The American Journal of dermatopathology (32:109)||2010|
H pylori status and angiogenesis factors in human gastric carcinoma.
MA5-11296 was used in immunohistochemistry to study Helicobacter pylori antigen and angiogenesis factors in human gastric carcinoma
|Mangia A,Chiriatti A,Ranieri G,Abbate I,Coviello M,Simone G,Zito FA,Montemurro S,Rucci A,Di Leo A,Tommasi S,Berloco P,Xu JM,Paradiso A||World journal of gastroenterology (12:5465)||2006|
The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
MA5-11296 was used in immunohistochemistry to study the value of neuroendocrine markers and p53 for predicting chemotherapeutic response and survival in advanced non-small cell lung cancer
|Gajra A,Tatum AH,Newman N,Gamble GP,Lichtenstein S,Rooney MT,Graziano SL||Lung cancer (Amsterdam, Netherlands) (36:159)||2002|
The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter.
MA5-11296 was used in ChIP assay, immunoprecipitation, and western blot to study the role of the ubiquitin-proteasome system in the transcriptional activation function of p53
|Zhu Q,Wani G,Yao J,Patnaik S,Wang QE,El-Mahdy MA,Praetorius-Ibba M,Wani AA||Oncogene (26:4199)||2007|
|Not Applicable||Not Cited||
Heightened susceptibility to chronic gastritis, hyperplasia and metaplasia in Kcnq1 mutant mice.
MA5-11296 was used in immunohistochemistry - paraffin section to use Kcnq1 mutant mice to study factor that promote gastric cancer
|Elso CM,Lu X,Culiat CT,Rutledge JC,Cacheiro NL,Generoso WM,Stubbs LJ||Human molecular genetics (13:2813)||2004|
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
MA5-11296 was used in immunocytochemistry to assess the activity of clinically used drugs and define the most effective treatment scheme in human gastric cancer cell lines
|Ricotti L,Tesei A,De Paola F,Ulivi P,Frassineti GL,Milandri C,Amadori D,Zoli W||Clinical cancer research : an official journal of the American Association for Cancer Research (9:900)||2003|
Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.
MA5-11296 was used in immunocytochemistry and immunoprecipitation to study the interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53
|Shinobu N,Maeda T,Aso T,Ito T,Kondo T,Koike K,Hatakeyama M||The Journal of biological chemistry (274:17003)||1999|